1 - 12 of 14 results
Physician talking with female patient
0.28 CME CREDIT

Hitting Diabetes Head-on: Improving Outcomes and Reducing Therapeutic Inertia With GLP-1 Receptor Agonists: AdaptED Module 1

An Interactive Learning ExperienceThis course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.25 CME/MOC
0.28 AANP | 0.28 Pharmacology

The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm. Learners will have the opportunity to evaluate their knowledge through multiple-choice and matching questions and case-based application.


Senior male puncturing finger for test
1 CME CREDIT

The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs.


Doctor with hand up about to speak
0.5 CME CREDIT

Updates From the 2021 EASD and ADA Annual Meetings on Dual GIP/GLP-1 RA Therapy: What You Should Know (Module 3)

An Interactive Learning Experience From ArcheMedX This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.50 CME/MOC
0.40 AANP | 0.40 Pharmacology


man checking his blood by poking his finger
0.5 CME CREDIT

The Role of GIP and GLP-1 in the Pathophysiology of T2DM and Why it Matters (Module 2)

An Interactive Learning Experience From ArcheMedX This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.50 CME/MOC
0.42 AANP | 0.42 Pharmacology


Doctor in protective shield mask talks to obese black woman
0.28 CME CREDIT

Hitting Diabetes Head-on: Improving Outcomes and Reducing Therapeutic Inertia With GLP-1 Receptor Agonists: AdaptED Module 2

An Interactive Learning Experience This course is hosted by an external partner. By clicking Launch Course, you will be directed off of Pri-Med.com. Upon completing the activity, you will be prompted to return to Pri-Med.com

0.25 CME/MOC
0.28 AANP | 0.28 Pharmacology

The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm. Learners will have the opportunity to evaluate their knowledge through multiple-choice and matching questions and case-based application.


Woman looking at insulin pen while doctor looks at her
1 CME CREDIT

Updates from American Diabetes Association 2021

1.00 CME/MOC
1.00 AANP | 1.00 Pharmacology

This session will cover some new data regarding treatment of type 2 diabetes: the GRADE study, SURPASS phase 3 program, the STEP program for treatment of obesity. It will also provide an update on studies using SGLT2 inhibitors and GLP 1 receptor agonists in people with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease.


Physician attending to patient

Maximum 50 words to introduce the activity The percentage of individuals with T2D achieving A1C <7% worsened from 2015-2018. Therapeutic inertia—failure to initiate or intensify treatment in a timely manner—is largely responsible for this problem. This program will support PCPs in overcoming therapeutic inertia through timely initiation and advancement of treatment with GLP-1 RAs and review guideline updates that support use of GLP-1 RA early in the treatment paradigm.


0.25 CME CREDIT

Boosting Weight Loss with Medications: New Support for GLP-1 RAs - Frankly Speaking EP 270

Guest: Jillian Joseph, MSPAS, PA-CMusic Credit: Richard Onorato

0.25 CME

You know GLP-1 RAs are an important class of agents for weight loss, but do you know which drug within this class is right for your patient? This brief podcast walks you through the recent evidence from the STEP 8 randomized clinical trial, comparing the efficacy and adverse reaction profiles for 2 GLP-1 RAs: semaglutide (Wegovy) and liraglutide (Saxenda). This is a must-listen for anyone looking to optimally individualize care for patients with obesity.


Coffee with Chopra: Episode 1
0.5 CME CREDIT

Advances in Diabetes and Reflections on Care

Episode 1: Coffee with Chopra

0.50 CME

Join Dr. Sanjiv Chopra, hepatologist, author, speaker, and thought leader as he interviews his guest, Dr. Martin Abrahamson, endocrinologist and associate professor at Harvard Medical School as they discuss major advances in diabetes as well as the promise of stem cell treatment, diet and weight loss in patients with diabetes, and advances in continuous glucose monitoring. The pair will end their conversation discussing what they have learned from patients over the years.